- Clinical Trials
- April 2025
- 60 Pages
Global
From €1343EUR$1,500USD£1,158GBP
- Report
- February 2026
- 250 Pages
Global
From €4021EUR$4,490USD£3,467GBP
- Report
- January 2026
- 196 Pages
Global
From €2239EUR$2,500USD£1,930GBP
- Clinical Trials
- April 2025
- 180 Pages
Global
From €2239EUR$2,500USD£1,930GBP
- Report
- April 2025
- 200 Pages
Global
From €7119EUR$7,950USD£6,138GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1119EUR$1,250USD£965GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1119EUR$1,250USD£965GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1119EUR$1,250USD£965GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2497EUR$2,789USD£2,153GBP
- Report
- November 2025
- 150 Pages
Global
From €4343EUR$4,850USD£3,745GBP
- Report
- August 2023
- 150 Pages
United States
From €3358EUR$3,750USD£2,895GBP
P-Selectin is a type of hematological drug used to treat a variety of conditions related to the blood, such as thrombosis, inflammation, and cancer. It is a type of cell adhesion molecule that binds to other cells, allowing them to stick together and form clots. P-Selectin is also involved in the process of leukocyte rolling, which is important for the immune system to respond to infection.
P-Selectin is used in a variety of treatments, including anticoagulants, anti-inflammatory drugs, and cancer therapies. It is also used in research to study the role of cell adhesion molecules in the development of diseases.
The P-Selectin market is highly competitive, with many companies offering products for different applications. Some of the major players in the market include Merck, Pfizer, Novartis, Sanofi, and Bristol-Myers Squibb. Other companies include AstraZeneca, GlaxoSmithKline, and Roche. Show Less Read more